Agreed. In biotech terms an extra 6 months may not seem like long, but as an investor, it seems like opportunity lost.
I still feel the buyback funds, or even the oversubscribed SPP could have been used to expand the team and maybe progress things with more speed. Who knows if I'm right or wrong, but storm have entered their P1 trial recently and released their preclinical study in 2021(and recent updated preclinical in 2022).
Agreed. In biotech terms an extra 6 months may not seem like...
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |